European Commission to ban two new psychoactive substances

1 May 2018
eu-europe

On Monday, the European Commission proposed to ban two new psychoactive substances (NPS) - cycloproplyfentanyl and methoxyacetylfentanyl - across the European Union.

These strong synthetic opioids can cause severe harm to health, sometimes resulting in death, and pose a growing threat to European citizens, the EC stated.

Commissioner for Migration, Home Affairs and Citizenship Dimitris Avramopoulos said: "We have taken quick and decisive steps to stop illicit drugs from spreading across Europe – in 2017 we have proposed to ban 16 new psychoactive substances and put in place stronger EU-wide rules. Today, we are following up on the efforts to better protect Europeans from dangerous drugs and propose to ban two new, potentially life-threatening, substances. We need to stay vigilant, continue our work and monitor the situation closely - in the coming weeks we will present a report with the main drug use trends in the EU."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical